ENANTA PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.32 USD | +0.68% |
|
-19.03% | +41.55% |
| Feb. 09 | Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating | MT |
| Feb. 07 | Transcript : Enanta Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 07, 2024 |
Chart calendar Enanta Pharmaceuticals, Inc.
67db777b.R12xVWCO50WVyxzZVcKej9NR0kYrzTLpvgiwtIFMmOU.MirkYxrcuBfmhy-KPvDV_rQ55XBf_HyuyT3o8-g79oByZdIzUMPKAtGgew~69f15049f283d0d038621beeca3a6647
Upcoming events on Enanta Pharmaceuticals, Inc.
Past events on Enanta Pharmaceuticals, Inc.
| 2024-03-13 10:40 am | Leerink Partners Global Biopharma Conference - Fireside Chat |
| 2024-03-06 05:00 pm | Annual General Meeting |
| 2024-02-13 11:20 am | Oppenheimer Healthcare Life Sciences Conference |
| 2024-02-07 04:30 pm | Q1 2024 Earnings Call |
| 2024-02-07 04:01 pm | Q1 2024 Earnings Release |
| 2024-01-10 12:45 pm | JPMorgan Healthcare Conference |
| 2023-11-29 07:55 am | Evercore ISI HealthCONx Conference |
| 2023-11-20 04:30 pm | Q4 2023 Earnings Call |
| 2023-11-20 04:01 pm | Q4 2023 Earnings Release |
| 2023-10-20 08:00 am | Investor Meeting - Key Opinion Leader |
| 2023-09-26 08:45 am | Cantor Global Healthcare Conference - Fireside Chat |
| 2023-09-17 02:00 pm | ESWI Influenza Conference - Abstract No: 663 |
| 2023-09-13 01:25 pm | Baird Global Healthcare Conference - Fireside Chat |
| 2023-09-12 04:30 pm | H.C. Wainwright Global Investment Conference |
| 2023-09-07 02:15 pm | Wells Fargo Healthcare Conference - Fireside Chat |
| 2023-08-07 04:30 pm | Q3 2023 Earnings Call |
| 2023-08-07 04:01 pm | Q3 2023 Earnings Release |
| 2023-06-07 12:30 pm | Jefferies Global Healthcare Conference |
| 2023-05-17 02:05 pm | RBC Global Healthcare Conference |
| 2023-05-16 09:30 am | JMP Securities Life Sciences Conference |
Annual results
| Fiscal Period | September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 205 210 -2.21% | 122 125 -1.7% | 97,1 99,6 -2.53% | 86,2 89,1 -3.25% | 79,2 77,1 2.69% | 68,8 |
|
EBITDA Million USD | Released Forecast Spread | 59,2 46,0 28.74% | -18,4 -44,0 58.14% | -85,2 -104 18.03% | -93,9 -127 26.06% | -107 -148 27.96% | -111 |
|
EBIT Million USD | Released Forecast Spread | 36,7 42,0 -12.47% | -41,6 -43,9 5.24% | -110 -105 -4.82% | -124 -127 2.31% | -137 -151 9.31% | -113 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 45,6 51,2 -11.06% | -35,0 -37,3 6.11% | -108 -103 -4.22% | -122 -125 2.61% | -131 -151 13.01% | -117 |
|
Net income Million USD | Released Forecast Spread | 46,4 49,6 -6.58% | -36,2 -25,4 -42.24% | -79,0 -81,2 2.67% | -122 -123 1.36% | -134 -152 11.91% | -110 |
|
EPS USD | Released Forecast Spread | 2,21 2,35 -5.96% | -1,81 -1,29 -40.34% | -3,92 -3,99 1.66% | -5,91 -5,93 0.32% | -6,38 -7,21 11.47% | -5,21 |
| Announcement Date | 21/11/19 | 23/11/20 | 22/11/21 | 21/11/22 | 20/11/23 | - |
Quarterly results
| Fiscal Period | September | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 27,6 27,4 1.03% | 18,7 20,7 -9.46% | 19,5 20,7 -6.05% | 20,3 23,1 -12.17% | 23,6 22,5 4.92% | 17,8 19,1 -6.63% | 18,9 16,7 12.88% | 18,9 17,5 8.2% | 18,0 21,9 -17.97% | 16,2 | 16,8 | 17,2 | 19,9 | 15,5 |
|
EBITDA Million USD | Released Forecast Spread | -24,0 | -32,0 | -26,0 | -21,0 | ||||||||||
|
EBIT Million USD | Released Forecast Spread | -30,4 -25,0 -21.62% | -33,8 -33,0 -2.59% | -32,5 -30,3 -7.48% | -27,0 -30,1 10.07% | -30,0 -34,0 11.63% | -39,5 -43,5 9.34% | -36,7 -55,0 33.31% | -31,0 -43,0 27.79% | -34,9 -23,6 -47.98% | -29,2 | -26,6 | -22,9 | -34,5 | -38,0 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -30,2 -25,3 -19.39% | -33,6 -33,3 -0.83% | -32,1 -29,9 -7.67% | -26,3 -29,8 11.63% | -29,0 -31,8 8.67% | -37,6 -42,1 10.63% | -34,8 -54,2 35.7% | -29,5 -46,6 36.69% | -34,0 -22,3 -52.88% | -28,3 | -27,4 | -25,2 | -34,5 | -36,5 |
|
Net income Million USD | Released Forecast Spread | -30,1 -22,8 -32.12% | -33,6 -30,2 -11.15% | -31,7 -28,6 -10.98% | -26,3 -28,8 8.58% | -29,0 -33,1 12.5% | -37,7 -39,6 4.98% | -39,1 -50,6 22.77% | -28,1 -44,7 37.13% | -33,4 -23,5 -42.05% | -27,2 | -26,8 | -24,7 | -30,2 | -35,9 |
|
EPS USD | Released Forecast Spread | -1,48 -1,11 -33.55% | -1,63 -1,43 -13.89% | -1,53 -1,37 -11.94% | -1,27 -1,34 4.99% | -1,39 -1,55 10.44% | -1,79 -1,92 6.84% | -1,86 -2,33 20% | -1,33 -2,15 38.04% | -1,58 -1,23 -28.93% | -1,30 | -1,22 | -1,03 | -1,44 | -1,70 |
| Announcement Date | 08/02/22 | 09/05/22 | 08/08/22 | 21/11/22 | 07/02/23 | 08/05/23 | 07/08/23 | 20/11/23 | 07/02/24 | - | - | - | - | - |
More events
Past sector events for Enanta Pharmaceuticals, Inc.
| 2024-04-17 | HINOVA PHARMACEUTICALS INC.: Q4 2023 Earnings Release |
| 2024-04-17 02:07 am | TELIX PHARMACEUTICALS LIMITED: March 2024 Sales and Revenue Release - Activities Report |
| 2024-04-10 04:10 pm | PHARVARIS N.V.: Q4 2023 Earnings Release |
| 2024-04-10 01:22 am | POLARIS GROUP: March 2024 Sales and Revenue Release |
| 2024-04-02 02:30 am | ABIVAX: Q4 2023 Earnings Release |
| 2024-04-01 09:00 am | BIOMEA FUSION, INC.: Q4 2023 Earnings Release |
| 2024-03-28 10:42 pm | ALPHAMAB ONCOLOGY: Q4 2023 Earnings Release |
| 2024-03-28 04:28 pm | CENTESSA PHARMACEUTICALS PLC: Q4 2023 Earnings Release |
| 2024-03-28 04:05 pm | ARRIVENT BIOPHARMA, INC.: Q4 2023 Earnings Release |
| 2024-03-28 07:10 am | HANGZHOU TIGERMED CONSULTING CO., LTD: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- ENTA Stock
- Calendar Enanta Pharmaceuticals, Inc.
